Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Malignant Melanoma

  Free Subscription


Articles published in J Clin Invest

Retrieve available abstracts of 17 articles:
HTML format



Single Articles


    May 2025
  1. WANG Y, Ohnuki H, Tran AD, Wang D, et al
    Induced clustering of SHP2-depleted tumor cells in vascular islands restores sensitivity to MEK/ERK inhibition.
    J Clin Invest. 2025;135:e181609.
    PubMed     Abstract available


  2. TORRES ACOSTA MA, Gurkan JK, Liu Q, Mambetsariev N, et al
    AMPK is necessary for Treg functional adaptation to microenvironmental stress during malignancy and viral pneumonia.
    J Clin Invest. 2025;135:e179572.
    PubMed     Abstract available


  3. HYUN H, Sun B, Yazdimamaghani M, Wielgus A, et al
    Tumor-specific surface marker-independent targeting of tumors through nanotechnology and bioorthogonal glycochemistry.
    J Clin Invest. 2025;135:e184964.
    PubMed     Abstract available


    April 2025
  4. STAEGER R, Tastanova A, Ghosh A, Winkelbeiner N, et al
    Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic T-cells in uveal melanoma patients.
    J Clin Invest. 2025 Apr 29:e181464. doi: 10.1172/JCI181464.
    PubMed     Abstract available


    January 2025
  5. ZHANG H, Wang Z, Wu J, Zheng YQ, et al
    Endothelial STING-JAK1 interaction promotes tumor vasculature normalization and antitumor immunity.
    J Clin Invest. 2025;135:e180622.
    PubMed     Abstract available


    December 2024
  6. WEN C, Wang L, Piffko A, Chen D, et al
    YTHDF1 loss in dendritic cells potentiates radiation-induced antitumor immunity via STING-dependent type I IFN production.
    J Clin Invest. 2024;134:e181612.
    PubMed     Abstract available


    October 2024
  7. NIELSEN AJ, Albert GK, Sanchez A, Chen J, et al
    DNA-PK inhibition enhances neoantigen diversity and increases T cell responses to immunoresistant tumors.
    J Clin Invest. 2024;134:e180278.
    PubMed     Abstract available


    September 2024
  8. LI ZJ, He B, Domenichini A, Satiaputra J, et al
    Pericyte phenotype switching alleviates immunosuppression and sensitizes vascularized tumors to immunotherapy in preclinical models.
    J Clin Invest. 2024;134:e179860.
    PubMed     Abstract available


  9. VERMA S, Budhu S, Serganova I, Dong L, et al
    Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models.
    J Clin Invest. 2024;134:e177606.
    PubMed     Abstract available


    May 2024
  10. CONWAY JR, Gillani R, Crowdis J, Reardon B, et al
    Somatic structural variants drive distinct modes of oncogenesis in melanoma.
    J Clin Invest. 2024 May 14:e177270. doi: 10.1172/JCI177270.
    PubMed     Abstract available


  11. HUANG F, Goncalves C, Bartish M, Remy-Sarrazin J, et al
    Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses.
    J Clin Invest. 2024;134:e181575.
    PubMed    


    April 2024
  12. ZHAN Y, Guo J, Yang W, Goncalves C, et al
    MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.
    J Clin Invest. 2024;134:e181338.
    PubMed    


    February 2024
  13. WU M, Hanly A, Gibson F, Fisher R, et al
    The CoREST repressor complex mediates phenotype switching and therapy resistance in melanoma.
    J Clin Invest. 2024 Feb 1:e171063. doi: 10.1172/JCI171063.
    PubMed     Abstract available


    December 2023
  14. KNIGHT DA, Ngiow SF, Li M, Parmenter T, et al
    Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
    J Clin Invest. 2023;133:e177489.
    PubMed    


    November 2023
  15. AJITH A, Mamouni K, Horuzsko DD, Musa A, et al
    Targeting TREM1 augments antitumor T cell immunity by inhibiting myeloid-derived suppressor cells and restraining anti-PD-1 resistance.
    J Clin Invest. 2023;133:e167951.
    PubMed     Abstract available


    August 2023
  16. HUANG F, Cai F, Dahabieh MS, Gunawardena K, et al
    Peroxisome disruption alters lipid metabolism and potentiates anti-tumor response with MAPK-targeted therapy in melanoma.
    J Clin Invest. 2023 Aug 24:e166644. doi: 10.1172/JCI166644.
    PubMed     Abstract available


    July 2023
  17. OZBAY KURT FG, Lasser S, Arkhypov I, Utikal J, et al
    Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target.
    J Clin Invest. 2023;133:e170762.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.